

ASX / MEDIA RELEASE

9th January 2017

First Half Worldwide Dose Sales Growth of 5.6%

Sydney, Australia; 9th January 2017 – Sirtex Medical Limited (ASX:SRX) today announces that unaudited worldwide dose sales of SIR-Spheres[®] Y-90 resin microspheres for the 6 months ended 31st December 2016 increased 5.6% over the prior corresponding period (pcp). The growth delivered was at the upper end of the 4-6% dose sales guidance provided on the 9th of December. The Americas recorded first half dose sales growth of 5.5% versus guidance of 4-6%, EMEA recorded first half dose sales growth of 4.1% versus guidance of 2-3% and APAC delivered growth of 10.2% versus guidance of 8-10%.

Sirtex will report its first half financial results on the 22nd of February, 2017.

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical

Sirtex Medical Limited (ASX:SRX) is an Australian-based global healthcare business working to improve outcomes in people with cancer. Our current lead product is a targeted radiation therapy for liver cancer. Over 73,000 doses have been supplied to treat patients with liver cancer at more than 1,000 medical centres in over 40 countries. For more information please visit www.sirtex.com.

For further information please contact:

Investor/Media Enquiries:

Dr Tom Duthy Global Investor Relations Manager Sirtex Medical Limited

Phone: +61 (0) 2 9964 8427 Email: tduthy@sirtex.com

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd